Compare VBNK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VBNK | PHAR |
|---|---|---|
| Founded | 1980 | 1988 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.4M | 793.4M |
| IPO Year | 2016 | 2020 |
| Metric | VBNK | PHAR |
|---|---|---|
| Price | $24.42 | $12.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $27.50 | ★ $35.70 |
| AVG Volume (30 Days) | ★ 78.3K | 14.4K |
| Earning Date | 01-07-2027 | 10-27-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.02 | $2.98 |
| Revenue Next Year | $37.94 | $8.95 |
| P/E Ratio | ★ $25.91 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.31 | $9.11 |
| 52 Week High | $25.00 | $21.34 |
| Indicator | VBNK | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 61.81 | 52.11 |
| Support Level | $21.53 | $11.83 |
| Resistance Level | N/A | $12.32 |
| Average True Range (ATR) | 0.87 | 0.46 |
| MACD | 0.15 | -0.11 |
| Stochastic Oscillator | 83.24 | 8.39 |
VersaBank is a Schedule I Canadian bank that provides mainly commercial lending and banking services to select niche markets in Canada and the United States. Its products and services include credit assets, deposits, and cybersecurity services through its wholly owned subsidiary. The bank operates through four segments: Digital Banking Canada and Digital Banking USA, both using a business-to-business model with proprietary financial technology to serve underserved markets; DRTC, which provides cybersecurity services and banking and financial technology development; and Digital Meteor, which owns proprietary technology supporting next-generation digital assets, including Real Bank Deposit Tokens (RBDTs). The majority of revenue comes from Digital Banking.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.